September 10, 2025 · Form 4 insider transaction
LaBrosse Nicole sold 6,760 shares of Halozyme Therapeutics, Inc. at $75.29 per share, a transaction worth $509.0K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.; Represents a weighted average sales price per share. These shares were sold at prices ranging from $74.56 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.